Page last updated: 2024-10-25

ciglitazone and Leukemia, Myeloid

ciglitazone has been researched along with Leukemia, Myeloid in 1 studies

ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.

Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mashayekhi, S1
Yousefi, B1
Tohidi, E1
Darband, SG1
Mirza-Aghazadeh-Attari, M1
Sadighparvar, S1
Kaviani, M1
Shafiei-Irannejad, V1
Kafil, HS1
Karimian, A1
Jadidi-Niaragh, F1
Majidinia, M1

Other Studies

1 other study available for ciglitazone and Leukemia, Myeloid

ArticleYear
Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin-resistance leukemia cancer cells to treatment.
    Journal of cellular biochemistry, 2019, Volume: 120, Issue:9

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Ce

2019